Articles from BIOTECH Patent News (August 1, 1999)

1-24 out of 24 article(s)

Title	Author	Type	Words
Abgenix receives patent on method for making mice that generate fully-human antibodies.			309
Aquila Biopharmaceuticals receives Phase II SBIR grant to develop tuberculosis vaccine using CD1 technology.			613
Biochem Pharma succeeds in invalidating Emory University's Australian patent application relating to 3TC.			229
Biomira begins BLP25 cancer vaccine clinical trial phase II lung cancer trial testing Immune Response to higher dose/high frequency vaccine treatment.			655
BTG to commercialize Coxsackievirus vectors for vaccine development and targeted gene therapy.			515
Carrington adds new patent and product for nutraceutical and pharmaceutical markets.			513
Cell Genesys and EntreMed announce research collaboration for cancer gene therapy.			753
CLOSURE Medical awarded United States patent relevant to skin adhesive.			266
Cortex to receive additional claims for enhancement of neurotrophic factor expression.			658
European Patent Office cites Hemispherx patents as precedent and dominant prior art in hepatitis treatments.			453
European Patent Office grants patent to Digene for its hybrid Capture technology platform.			311
EXACT Laboratories' fifth United States patent.			376
Human Genome Sciences obtains United States patent.			89
Inlet Medical reports issuance of patent for method of using needle-point suture passer.			216
Kinetek Pharmaceuticals awarded patent for KP-102, orally active type 2 diabetes therapy.			621
NAPM testimony to Senate Judiciary Committee condemns drug patent extensions.			1175
Osiris Therapeutics and Cambrex subsidiary BioWhittaker form collaboration for adult stem cells.			705
Principia Pharmaceutical formed to develop therapeutic proteins with prolonged activity.			442
Targeted Genetics reacquires European rights to E1A cancer product.			671
THM Biomedical announces new patent issued for bone graft substitute technology.			310
THM Biomedical receives patent for a method and device to promote repair of articular cartilage.			311
Valentis issued third patent for GeneSwitch technology.			548
Vitro Diagnostics receives United States notice of allowance.			334
Watson sues to stop Rhone-Poulenc Rorer and its successor, Aventis, from producing or selling Cardizem CD.			1050